We assign a fundamental rating of 3 out of 10 to CCXI. CCXI was compared to 525 industry peers in the Biotechnology industry. CCXI has a bad profitability rating. Also its financial health evaluation is rather negative. CCXI is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

CCXI had negative earnings in the past year.
In the past year CCXI has reported a negative cash flow from operations.

1.2 Ratios

		Industry Rank	Sector Rank
ROA	-31.74%
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

		Industry Rank	Sector Rank
OM	-353.17%
PM (TTM)	-357.01%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CCXI does not have a ROIC to compare to the WACC, probably because it is not profitable.
CCXI has more shares outstanding than it did 1 year ago.
The debt/assets ratio for CCXI is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 9.70 indicates that CCXI is not in any danger for bankruptcy at the moment.
CCXI has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Altman-Z	9.7

ROIC/WACCN/A

WACC9.62%

2.3 Liquidity

A Current Ratio of 4.54 indicates that CCXI has no problem at all paying its short term obligations.
CCXI has a Quick Ratio of 4.47. This indicates that CCXI is financially healthy and has no problem in meeting its short term obligations.

		Industry Rank	Sector Rank
Current Ratio	4.54
Quick Ratio	4.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CCXI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.78%.
CCXI shows a strong growth in Revenue. In the last year, the Revenue has grown by 72.49%.
Measured over the past years, CCXI shows a very strong growth in Revenue. The Revenue has been growing by 21.96% on average per year.

EPS 1Y (TTM)-6.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%21.43%

Revenue 1Y (TTM)72.49%

Revenue growth 3Y-9.08%

Revenue growth 5Y21.96%

Sales Q2Q%548.81%

3.2 Future

Based on estimates for the next years, CCXI will show a very strong growth in Earnings Per Share. The EPS will grow by 47.34% on average per year.
CCXI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 134.59% yearly.

EPS Next Y9.69%

EPS Next 2Y37.13%

EPS Next 3Y41.06%

EPS Next 5Y47.34%

Revenue Next Year117.77%

Revenue Next 2Y157.52%

Revenue Next 3Y130.02%

Revenue Next 5Y134.59%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CCXI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCXI. No positive earnings are expected for the next year.